Syros Pharmaceuticals Presents Data Demonstrating Significant Anti - Cancer Activity of SY - 1425 in Preclinical Models of Acute Myeloid Leukemia

Syros Pharmaceuticals Presents Data Demonstrating Significant Anti - Cancer Activity of SY - 1425 in Preclinical Models of Acute Myeloid Leukemia

April 18, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals today announced that SY-1425, a potent and selective retinoic acid receptor alpha (RARα) agonist, was observed to inhibit the growth of cancer cells and prolong survival in in vivo models of acute myeloid leukemia (AML) with a novel RARA biomarker discovered by the Company. The biomarker was found in approximately 25 percent of AML and myelodysplastic syndrome (MDS) patient tissue samples. These data were presented at the American Association of Cancer Research (AACR) Annual Meeting in New Orleans.

Seventh Sense Biosystems Launches Pivotal Trial For Groundbreaking TAP Diagnostic Blood Collection Device

Seventh Sense Biosystems Launches Pivotal Trial For Groundbreaking TAP Diagnostic Blood Collection Device

April 13, 2016

MEDFORD, Mass., April 13, 2016/PRNEWSWIRE/ – Seventh Sense Biosystems, a privately held health technology company developing a breakthrough painless diagnostic blood collection platform, initiated a pivotal registration trial for its TAP™ Touch Activated Phlebotomy device. The company expects to file for marketing authorization in the United States and in the European Union in the second quarter of 2016, and anticipates receiving its E.U. CE Mark and U.S. regulatory approval later this summer.

UChicago and Evelo Biosciences sign licensing deal for microbiome-based cancer immunotherapy

UChicago and Evelo Biosciences sign licensing deal for microbiome-based cancer immunotherapy

April 7, 2016

CAMBRIDGE, Mass., April 7, 2016/PRNewswire/--Evelo Biosciences and the University of Chicago announced today that they have entered into an exclusive worldwide license agreement to develop and commercialize a microbiome-based cancer immunotherapy. The cancer therapy, developed in the laboratories of UChicago researcher Thomas Gajewski, employs select gut microbes to boost the immune system’s attack on cancer cells and improve the efficacy of anti-cancer drugs.

Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy

Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy

March 30, 2016

CAMBRIDGE, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1/2, multicenter, international, open-label study, sponsored by Celgene Corporation, of AG-221 or AG-120 in combination with VIDAZA® (azacitidine for injection) in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are not eligible for intensive chemotherapy.

Editas Medicine Reports Fourth Quarter and Full Year 2015 Financial Results

Editas Medicine Reports Fourth Quarter and Full Year 2015 Financial Results

March 30, 2016

Well-positioned to advance multiple programs and continue expansion of genome editing platform

Cash balance of approximately $230 million funds diversified pipeline

Executive team and board of directors expanded to strengthen leadership

CAMBRIDGE, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT) today reported financial results for the fourth quarter and full year ended December 31, 2015, and provided an update on key achievements and upcoming events.

Moderna Therapeutics Appoints Saqib Islam as Chief Business Officer

Moderna Therapeutics Appoints Saqib Islam as Chief Business Officer

March 28, 2016

Seasoned Industry Leader to Join Moderna’s Executive Team

Quanterix Raises $46 Million in Series D Financing

Quanterix Raises $46 Million in Series D Financing

March 23, 2016

Lexington, Mass. – March 23, 2016 Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced it secured $46 million in Series D funding from both new and existing investors. This infusion of capital will allow Quanterix to build on the significant growth realized in the last two years.

BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS® Platform

BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS® Platform

March 15, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today reported financial results for the fourth quarter and full year 2015. Additionally, the Company announced a shift in its research and discovery strategy to focus on the development of innovative medicines, primarily in cancer.

Publication in Science Further Validates Importance of Gene Control Research in Yielding New Insights into Diagnosing and Treating Cancer

Publication in Science Further Validates Importance of Gene Control Research in Yielding New Insights into Diagnosing and Treating Cancer

March 3, 2016

CAMBRIDGE, Mass., March 3, 2016 – Syros Pharmaceuticals announced today that research from its scientific co-founder Richard Young, Ph.D., reveals a new mechanism by which genetic alterations in non-coding regions of the DNA fuel cancer growth, providing further validation for Syros’ pioneering approach to discover and develop medicines that control the expression of genes with the aim of treating cancer and other serious diseases.

Acceleron Pharma Reports Fourth Quarter and Year Ended 2015 Financial and Operational Results and Recent Highlights

Acceleron Pharma Reports Fourth Quarter and Year Ended 2015 Financial and Operational Results and Recent Highlights

February 25, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2015.